<DOC>
	<DOCNO>NCT02574286</DOCNO>
	<brief_summary>To evaluate effect VPRIV® therapy patient type 1 Gaucher disease measure change lumbar spine ( LS ) bone mineral density ( BMD ) 24 month treatment .</brief_summary>
	<brief_title>Phase 4 Study Evaluate Effect Velaglucerase Alfa ( VPRIV® ) Patients With Type 1 Gaucher Disease Through IV Administration VPRIV® Over 2 Years</brief_title>
	<detailed_description />
	<mesh_term>Gaucher Disease</mesh_term>
	<mesh_term>Hydroxycholecalciferols</mesh_term>
	<criteria>1 . The patient document diagnosis type 1 Gaucher disease , document deficient glucocerebrosidase ( GCB ) activity leukocyte ( whole blood ) culture skin fibroblast . Diagnosis dry blood spot test sufficient . Diagnosis may base result obtain prior Screening document patient 's medical history . 2 . Patients must LS BMD Zscore &lt; 1 measure DXA screen phase . 3 . Patient treatmentnaïve , ie , receive ERT SRT 12 month prior enrollment . 4 . The patient ≥18 ≤65 year age . 5 . Female patient childbearing potential must agree use medically acceptable method contraception time study . 6 . The patient , patient 's parent ( ) legal guardian ( ) , applicable , understands nature , scope , possible consequence study provide write informed consent approve Institutional Review Board/Independent Ethics Committee ( IRB/IEC ) . 7 . The patient must sufficiently cooperative participate clinical study judge investigator . Exclusion criteria 1 . Neurological symptom indicate patient type 3 Gaucher disease . 2 . A significant comorbidity , , determine investigator , might compromise study assessment , affect study data confound study result ( eg , malignancy , primary biliary cirrhosis , autoimmune liver disease , etc ) . 3 . Any osteoporosisspecific treatment ( eg , bisphosphonates ) treatment erythropoietin ( erythropoietinlike substance ) past year . 4 . Structural , jointassociated bone damage extent severity investigator deems could impact participation study assessment relevant study endpoint ( eg , pain ) . 5 . The patient pregnant lactating . 6 . The patient splenectomy . 7 . The patient enrol another clinical study involve clinical investigation use investigational product ( drug device ) within 30 day prior study enrollment time study . 8 . Severe vitamin D deficiency level would expect result osteomalacia ( 25hydroxyvitamin D &lt; 10 ng/mL [ 25 nmol/L ] ) . If mild vitamin D insufficiency screen ( 25hydroxyvitamin D &gt; 10 &lt; 30 ng/mL ) treat 4000 IU 25 hydroxyvitamin D per day 1 month rescreen . 9 . The patient previously interrupt ERT safety reason . 10 . The patient hypersensitivity active substance excipients .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>